OmniAb Income Taxes 2022-2025 | OABI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

OmniAb income taxes from 2022 to 2025. Income taxes can be defined as the total amount of income tax expense for the given period.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

OmniAb income taxes from 2022 to 2025. Income taxes can be defined as the total amount of income tax expense for the given period.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$75.9B
Zoetis (ZTS)	$67.3B
Takeda Pharmaceutical (TAK)	$46.3B
Daiichi Sankyo, - (DSNKY)	$45.5B
BeOne Medicines - (ONC)	$32.4B
Sandoz Group AG (SDZNY)	$25.8B
Summit Therapeutics (SMMT)	$19.7B
Merck (MKKGY)	$16.7B
Shionogi (SGIOY)	$14B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.1B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$10.3B
Stevanato Group S.p.A (STVN)	$7.4B
Corcept Therapeutics (CORT)	$7.3B
Madrigal Pharmaceuticals (MDGL)	$7B
Ionis Pharmaceuticals (IONS)	$6.7B
Grifols, S.A (GRFS)	$6.6B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.3B
Procaps Group, S.A (PROCF)	$3.2B
Hypermarcas (HYPMY)	$3B
Crinetics Pharmaceuticals (CRNX)	$2.9B
NewAmsterdam Pharma (NAMS)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
Ocular Therapeutix (OCUL)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.8B